Materials
Presentations
Welcome and Introductory Remarks
Veronica Miller, Forum for Collaborative Research
Adrian Di Bisceglie, Hightide Therapeutics
Kris Kowdley, Liver Institute Northwest
Session I: Connecting The Clinic with Drug Development
Implementing Recent Treatment Guidelines for PSC Clinical Trial Enrollment
Michael Trauner, Medical University of Vienna
Panel Discussion
Mary Vyas, PSC Partners Seeking a Cure Canada
Sindee Weinbaum, Hetz - Israeli Association for the Health of the Liver/European Liver Patients' Association
Martine Walmsley, PSC Support
Session II: Gaps and Barriers: Reflecting on Ongoing Programs
What can we look at other than ALP? Innovating Biomarkers for PSC Diagnosis, Prognosis and Treatment Response
Mette Vesterhus, Norwegian PSC Research CenterWhat can we look at other than ALP? Innovating Biomarkers for PSC Diagnosis, Prognosis and Treatment Response
Diana Leeming, Nordic BiosciencePanel Discussion Surrogate Endpoints for PSC: Integrating Biomarkers into Clinical Trials
Michelle Berrey, Intercept Pharmaceuticals
Lisa Boyette, Gilead Sciences, Inc.
Matthew Frankel, Chemomab Therapeutics
Eric Lefebvre, Pliant Therapeutics
Leigh MacConell, Ipsen
Charles McWherter, CymaBay Therapeutics, Inc.
Benjamin Miller, Ipsen
Tiago Nunes, Mirum Pharmaceuticals
Tim Watkins, Gilead Sciences, Inc.
Session III: Collaborations Across Datasets
Overview
Veronica Miller, Forum for Collaborative Research
Session IV: Next Steps
Comments
Adrian Di Bisceglie, HighTide Therapeutics
Kris Kowdley, Liver Institute Northwest
Veronica Miller, Forum for Collaborative Research
* Indicates remote participation